CompanyAARDNasdaqSan Diego, CA

Aardvark Therapeutics, Inc.

Aardvark Therapeutics develops small-molecule therapeutics targeting hunger signaling for Prader-Willi Syndrome and metabolic diseases.

SEC EDGAR ClinicalTrials.gov aardvarktherapeutics.com

10-KSep 28Latest SEC filing

Sep 8Latest story

September 2026

Aardvark posts Phase 2 results for ARD-101 in Prader-Willi Syndrome

Sep 8Trial updateAardvark Therapeutics, Inc.ARD-101

August 2026

Aardvark to review unblinded ARD-101 data in Q3 2026 amid FDA clinical hold

Aug 11Quarterly updateAardvark Therapeutics, Inc.ARD-101